| Year |
Citation |
Score |
| 2018 |
Camblin AJ, Pace EA, Adams S, Curley MD, Rimkunas V, Nie L, Tan G, Bloom T, Iadevaia S, Baum J, Minx C, Czibere A, Louis CU, Drummond DC, Nielsen UB, et al. Dual inhibition of IGF-1R and ErbB3 enhances the activity of gemcitabine and nab-paclitaxel in preclinical models of pancreatic cancer. Clinical Cancer Research : An Official Journal of the American Association For Cancer Research. PMID 29549161 DOI: 10.1158/1078-0432.Ccr-17-2262 |
0.311 |
|
| 2017 |
Mathews S, Finn G, Kudla AJ, Rimkunas V, Laivins P, MacBeath G, Czibere A, Baum J. Abstract A19: Identification of Heregulin (HRG) expression as a driver of a difficult-to-treat cancer phenotype and development of a companion diagnostic for the HRG-ErbB3 targeting drug seribantumab Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A19 |
0.307 |
|
| 2017 |
Finn G, Zhang H, Blois A, Mathews s, Kudla A, Baum J, Cieslewicz M, macbeath g, Adiwijaya B, Czibere A. Abstract A14: A randomized trial of exemestane +/- seribantumab (MM-121) in postmenopausal women with locally advanced or metastatic ER/PR+ HER2- breast cancer: Final analysis and extended subgroup analysis Clinical Cancer Research. 23. DOI: 10.1158/1557-3265.Pmccavuln16-A14 |
0.312 |
|
| 2015 |
Pace E, Adams S, Camblin A, Curley M, Rimkunas V, Nie L, Iadevaia S, Tan G, Baum J, Czibere AG, Lugovskoy A. Effect of MM-141 on gemcitabine and nab-paclitaxel potentiation in preclinical models of pancreatic cancer through induction of IGF-1R and ErbB3 degradation. Journal of Clinical Oncology. 33: 289-289. DOI: 10.1200/Jco.2015.33.3_Suppl.289 |
0.359 |
|
| 2014 |
Fitzgerald JB, Johnson BW, Baum J, Adams S, Iadevaia S, Tang J, Rimkunas V, Xu L, Kohli N, Rennard R, Razlog M, Jiao Y, Harms BD, Olivier KJ, Schoeberl B, et al. MM-141, an IGF-IR- and ErbB3-directed bispecific antibody, overcomes network adaptations that limit activity of IGF-IR inhibitors. Molecular Cancer Therapeutics. 13: 410-25. PMID 24282274 DOI: 10.1158/1535-7163.Mct-13-0255 |
0.327 |
|
| 2013 |
Adams S, Baum J, Sparta B, Rimkunas V, Tang J, Pace E, Rosenthal S, Camblin A, Iadevaia S, Czibere A, Nielsen U, Lugovskoy A. Abstract C169: MM-141, a bispecific antibody inhibitor of PI3K/AKT/mTOR, attenuates tumor growth and potentiates everolimus in mouse models of anti-hormonal therapy-resistant ER/PR+ breast cancer. Molecular Cancer Therapeutics. 12. DOI: 10.1158/1535-7163.Targ-13-C169 |
0.339 |
|
| 2012 |
Johnson B, Jiao Y, Schoeberl B, Nielsen U, Fitzgerald J, Lugovskoy A, Adams S, Baum J, Tang J, Iadevaia S, Kohli N, Rennard R, Sundararajan P, Xu L. Abstract A38: MM-141, a novel tetravalent bispecific antibody directed at IGF-1R and ErbB3 that inhibits pancreatic tumor cell growth and potentiates the effects of gemcitabine. Cancer Research. 72. DOI: 10.1158/1538-7445.Panca2012-A38 |
0.353 |
|
| 2011 |
Lugovskoy A, Johnson B, Baum J, Adams S, Tang J, Kohli N, Rennard R, Xu L, Jiao Y, Nilesen U, Fitzgerald J. Abstract B205: Therapeutically targeting redundant, growth factor-induced prosurvival signaling with MM-141, a novel bispecific antibody targeting IGF-1R and ErbB3. Molecular Cancer Therapeutics. 10. DOI: 10.1158/1535-7163.Targ-11-B205 |
0.346 |
|
| 2007 |
Baum JS, Arama E, Steller H, McCall K. The Drosophila caspases Strica and Dronc function redundantly in programmed cell death during oogenesis. Cell Death and Differentiation. 14: 1508-17. PMID 17464325 DOI: 10.1038/Sj.Cdd.4402155 |
0.607 |
|
| 2005 |
Baum JS, St George JP, McCall K. Programmed cell death in the germline. Seminars in Cell & Developmental Biology. 16: 245-59. PMID 15797835 DOI: 10.1016/J.Semcdb.2004.12.008 |
0.581 |
|
| 2004 |
McCall K, Baum JS, Cullen K, Peterson JS. Visualizing apoptosis. Methods in Molecular Biology (Clifton, N.J.). 247: 431-42. PMID 14707364 |
0.553 |
|
| 2003 |
Laundrie B, Peterson JS, Baum JS, Chang JC, Fileppo D, Thompson SR, McCall K. Germline cell death is inhibited by P-element insertions disrupting the dcp-1/pita nested gene pair in Drosophila. Genetics. 165: 1881-8. PMID 14704173 |
0.589 |
|
| Low-probability matches (unlikely to be authored by this person) |
| 2012 |
Baum J, Johnson B, Adams S, Tang J, Kohli N, Rennard R, Sundararajan P, Xu L, Jiao Y, Schoeberl B, Nielsen U, Fitzgerald J, Lugovskoy A. Abstract 2719: MM-141, a novel bispecific antibody co-targeting IGF-1R and ErbB3, blocks ligand-induced signaling and demonstrates antitumor activity Cancer Research. 72: 2719-2719. DOI: 10.1158/1538-7445.Am2012-2719 |
0.292 |
|
| 2015 |
Lugovskoy AA, Curley M, Baum J, Adams S, Iadevaia S, Rimkunas V, Camblin A, Nie L, Tan G, Johnson B, Mathews S, Horgan K, Louis CU, Czibere AG, Arnedos M, et al. Abstract CT237: Preclinical characterization and first-in-human study of MM-141, a dual antibody inhibitor of IGF-1R and ErbB3 Cancer Research. 75. DOI: 10.1158/1538-7445.Am2015-Ct237 |
0.291 |
|
| 2017 |
Finn G, Zhang H, Blois A, Mathews S, Kudla A, Baum J, Demars N, Cieslewicz M, Czibere A. Abstract P6-15-02: Phenotypically distinct HRG positive cancer cells impact standard of care therapies in metastatic breast cancer models Cancer Research. 77. DOI: 10.1158/1538-7445.Sabcs16-P6-15-02 |
0.274 |
|
| 2016 |
Ko AH, Murray J, Horgan KE, Dauer J, Curley M, Baum J, Louis CU, Lugovskoy A. A multicenter phase II study of istiratumab (MM-141) plus nab-paclitaxel (A) and gemcitabine (G) in metastatic pancreatic cancer (MPC). Journal of Clinical Oncology. 34: TPS481-TPS481. DOI: 10.1200/Jco.2016.34.4_Suppl.Tps481 |
0.27 |
|
| 2013 |
Xu L, Kohli N, Rennard R, Jiao Y, Razlog M, Zhang K, Baum J, Johnson B, Tang J, Schoeberl B, Fitzgerald J, Nielsen U, Lugovskoy AA. Rapid optimization and prototyping for therapeutic antibody-like molecules. Mabs. 5: 237-54. PMID 23392215 DOI: 10.4161/Mabs.23363 |
0.261 |
|
| 2023 |
Diwanji R, O'Brien NA, Choi JE, Nguyen B, Laszewski T, Grauel AL, Yan Z, Xu X, Wu J, Ruddy DA, Piquet M, Pelletier MR, Savchenko A, Charette L, Rodrik-Outmezguine V, ... Baum J, et al. Targeting the IL-1β pathway for cancer immunotherapy remodels the tumor microenvironment and enhances antitumor immune responses. Cancer Immunology Research. PMID 37040466 DOI: 10.1158/2326-6066.CIR-22-0290 |
0.12 |
|
| 2019 |
Felip E, de Braud FG, Maur M, Loong HH, Shaw AT, Vansteenkiste JF, John T, Liu G, Lolkema MP, Selvaggi G, Giannone V, Cazorla P, Baum J, Balbin OA, Wang LV, et al. Ceritinib plus nivolumab in patients with advanced ALK-rearranged non-small-cell lung cancer: results of an open-label, multicenter, phase 1B study: Ceritinib plus nivolumab in ALK-rearranged NSCLC. Journal of Thoracic Oncology : Official Publication of the International Association For the Study of Lung Cancer. PMID 31634667 DOI: 10.1016/j.jtho.2019.10.006 |
0.118 |
|
| 1995 |
Simon JS, Baum JS, Moore SA, Kasson BG. Arginine vasopressin stimulates protein synthesis but not proliferation of cultured vascular endothelial cells. Journal of Cardiovascular Pharmacology. 25: 368-75. PMID 7769800 DOI: 10.1097/00005344-199503000-00004 |
0.116 |
|
| 2021 |
Caldwell C, Rottman JB, Paces W, Bueche E, Reitsma S, Gibb J, Adisetiyo V, Haas MS, Heath H, Newman W, Baum J, Gianani R, Kagey MH. Validation of a DKK1 RNAscope chromogenic in situ hybridization assay for gastric and gastroesophageal junction adenocarcinoma tumors. Scientific Reports. 11: 9920. PMID 33972574 DOI: 10.1038/s41598-021-89060-3 |
0.104 |
|
| 2024 |
Wise DR, Pachynski RK, Denmeade SR, Aggarwal RR, Deng J, Febles VA, Balar AV, Economides MP, Loomis C, Selvaraj S, Haas M, Kagey MH, Newman W, Baum J, Troxel AB, et al. A Phase 1/2 multicenter trial of DKN-01 as monotherapy or in combination with docetaxel for the treatment of metastatic castration-resistant prostate cancer (mCRPC). Prostate Cancer and Prostatic Diseases. PMID 38341461 DOI: 10.1038/s41391-024-00798-z |
0.098 |
|
| 2020 |
Wong CC, Baum J, Silvestro A, Beste MT, Bharani-Dharan B, Xu S, Wang YA, Wang X, Prescott MF, Krajkovich L, Dugan M, Ridker PM, Martin AM, Svensson EC. Inhibition of IL-1β by canakinumab may be effective against diverse molecular subtypes of lung cancer: an exploratory analysis of the CANTOS trial. Cancer Research. PMID 33023946 DOI: 10.1158/0008-5472.CAN-19-3176 |
0.084 |
|
| 1991 |
Baum JS. Design features of a biotechnology laboratory environment. Occupational Medicine (Philadelphia, Pa.). 6: 227-54. PMID 2047975 |
0.045 |
|
| 1998 |
Baum JS, Marzocco KE, Hansen LI, Brown CA. Batching, treating keys to moving refined products in crude-oil line Oil and Gas Journal. 96: 49-55. |
0.04 |
|
| 1999 |
Lyga JW, Chang JH, Theodoridis G, Baum JS. Structural replacements for the benzoxazinone protox inhibitors Pesticide Science. 55: 281-287. DOI: 10.1002/(SICI)1096-9063(199903)55:3<281::AID-PS930>3.0.CO;2-G |
0.04 |
|
| 2006 |
Baum JS, DiBerardinis LJ. Open laboratories: Operational and safety issues or how to determine if open laboratories will work for you Journal of Chemical Health and Safety. 13: 15-19. DOI: 10.1016/j.chs.2005.01.013 |
0.035 |
|
| 2013 |
DiBerardinis LJ, Baum JS, First MW, Gatwood GT, Seth AK. Guidelines for Laboratory Design: Health, Safety, and Environmental Considerations: Fourth Edition Guidelines For Laboratory Design: Health, Safety, and Environmental Considerations: Fourth Edition. DOI: 10.1002/9781118633816 |
0.025 |
|
| 1998 |
Theodoridis G, Baum JS, Chang JH, Crawford SD, Hotzman FW, Lyga JW, Maravetz LL, Suarez DP, Hatterman-Valenti H. Synthesis and Herbicidal Activity of Fused Benzoheterocyclic Ring Systems Acs Symposium Series. 686: 55-66. |
0.022 |
|
| 1987 |
Baum JS, Davies HML, Shook DA, Smith HD. Diazotransfer reactions with p-acetamidobenzenesulfonyl azide Synthetic Communications. 17: 1709-1716. DOI: 10.1080/00397918708063988 |
0.021 |
|
| 1994 |
Baum JS, Baum GR, Thompson PR, Humphrey JD. Stable isotopic evidence for relative and eustatic sea-level changes in Eocene to Oligocene carbonates, Baldwin County, Alabama Geological Society of America Bulletin. 106: 824-839. DOI: 10.1130/0016-7606(1994)106<0824:SIEFRA>2.3.CO;2 |
0.018 |
|
| 1997 |
Falls WF, Baum JS, Prowell DC. Physical stratigraphy and hydrostratigraphy of Upper Cretaceous and Paleocene sediments, Burke and Screven Counties, Georgia Southeastern Geology. 36: 153-176. |
0.018 |
|
| 2003 |
DiBerardinis LJ, First MW, Party E, Smith TC, Warfield CA, Carpenter JP, Cook JL, Walters DB, Flynn MR, Galson EL, Greenley PL, Hitchings DT, Knutson GW, Price JM, Baum JS, et al. Report of the Howard Hughes Medical Institute's workshop on the performance of laboratory chemical hoods. Aiha Journal : a Journal For the Science of Occupational and Environmental Health and Safety. 64: 228-37. PMID 12688847 DOI: 10.1202/1542-8125(2003)64<228:ROTHHM>2.0.CO;2 |
0.017 |
|
| 2000 |
Baum JS, Deivert RG. Atraumatic osteochondral fracture and osteoarthritis in a collegiate volleyball player: a case report. Journal of Athletic Training. 35: 80-5. PMID 16558614 |
0.01 |
|
| 1987 |
Baum JS, Condon ME, Shook DA. Nickel-catalyzed transformations of 2,1-benzisoxazoles with organozinc reagents Journal of Organic Chemistry. 52: 2983-2988. |
0.01 |
|
| 1981 |
Baum JS, Schultz JM. RAPID MEASUREMENTS OF ELASTIC MODULUS AND DENSITY IN POLYPROPYLENE SHEET DURING AGING. Journal of Applied Polymer Science. 26: 1579-1584. DOI: 10.1002/App.1981.070260513 |
0.01 |
|
| 1980 |
Hatch CE, Baum JS, Takashima T, Kondo K. Stereospecific total synthesis of the potent synthetic pyrethroid NRDC 182 Journal of Organic Chemistry. 45: 3281-3285. |
0.01 |
|
| 1976 |
Baum JS, Viehe HG. Synthesis and cycloaddition reactions of acetylenic iminium compounds Journal of Organic Chemistry. 41: 183-187. |
0.01 |
|
| 1974 |
Potts KT, Baum JS. The chemistry of cyclopropenones Chemical Reviews. 74: 189-213. |
0.01 |
|
| 1973 |
Baum JS, Prather BV. Oily waste water treatment | INDUSTRIAL OILY WASTE CONTROL Amer.Petrol.Inst.Publ.. 47. |
0.01 |
|
| Hide low-probability matches. |